The Long Run with Luke Timmerman podcast

Ep199: Martin Burke on Making Small Molecule Medicines for the AI Era

21/4/2026

The Long Run with Luke Timmerman

0:00

1:10:08

Marty Burke, a professor of chemistry at the University of Illinois and co-founder of Excelsior Sciences, on making small molecule synthesis more automated for AI.

Otros episodios de "The Long Run with Luke Timmerman"

Ep199: Martin Burke on Making Small Molecule Medicines for the AI Era
21/4/2026
1:10:08
Marty Burke, a professor of chemistry at the University of Illinois and co-founder of Excelsior Sciences, on making small molecule synthesis more automated for AI.
Ep198: Abbas Kazimi on Computation and Culture for Drug Discovery
7/4/2026
1:16:43
Abbas Kazimi, CEO of Boston-based Nimbus Therapeutics, on computation and culture for drug discovery.
No te pierdas ningún episodio de “The Long Run with Luke Timmerman”. Síguelo en la aplicación gratuita de GetPodcast.
Ep197: Viswa Colluru on Discovering Drugs Inspired by Mother Nature
31/3/2026
1:16:57
Viswa Colluru, founder and CEO of Boulder, Colo.-based Enveda, on drug discovery with a chemistry platform inspired by natural products.
Ep196: Otello Stampacchia on Europe's Biotech Crisis
17/3/2026
1:03:17
Otello Stampacchia, founder and managing director of Omega Funds, on attempting to reform Europe's biotech investment climate.
Ep195: Ken Song on T-cell Engagers for Autoimmune Diseases
3/3/2026
1:05:45
Ken Song, CEO of San Diego-based Candid Therapeutics, on developing bispecific T-cell engaging antibodies for autoimmune disease.
Ep194: Ansu Satpathy on Cancer and Autoimmune Drug Discovery
17/2/2026
1:08:54
Ep194: Ansu Satpathy on Cancer and Autoimmune Drug Discovery by Timmerman Report
Ep193: Ron Renaud on Helping People Lose Weight With GLP-1 Medicines
22/1/2026
1:05:10
Ron Renaud, CEO of Waltham, Mass.-based Kailera Therapeutics, on developing GLP-1 based medicines to help people lose weight and live healthier lives.
Ep192: Kate Haviland on Following the Science to Precision Immunology
8/1/2026
1:26:06
Kate Haviland, former CEO of Blueprint Medicines, on how the company transitioned to a precision immunology company and was acquired by Sanofi for $9.5 billion.
Ep191: Emily Conley on Small Molecules to Correct a Rare Kidney Disease
15/12/2025
1:07:34
Emily Conley, CEO of Berkeley, CA-based Renasant Bio, on developing small molecule correctors and potentiators for autosomal dominant polycystic kidney disease (ADPKD).
Ep190: Neil Kumar on Building a Rare Disease Drug Company
20/11/2025
1:13:12
Neil Kumar is founder and CEO of Palo Alto, Calif.-based BridgeBio Pharma, a rare disease drug developer.

Más episodios

Descubre los mejores podcast en la aplicación gratuita de GetPodcast.

Suscríbete a tus podcast favoritos, escucha episodios cuando estés sin conexión y déjate sorprender por las recomendaciones personalizadas.

Una empresa de

Ep199: Martin Burke on Making Small Molecule Medicines for the AI Era

The Long Run with Luke Timmerman

Otros episodios de "The Long Run with Luke Timmerman"

Ep199: Martin Burke on Making Small Molecule Medicines for the AI Era

Ep198: Abbas Kazimi on Computation and Culture for Drug Discovery

Ep197: Viswa Colluru on Discovering Drugs Inspired by Mother Nature

Ep196: Otello Stampacchia on Europe's Biotech Crisis

Ep195: Ken Song on T-cell Engagers for Autoimmune Diseases

Ep194: Ansu Satpathy on Cancer and Autoimmune Drug Discovery

Ep193: Ron Renaud on Helping People Lose Weight With GLP-1 Medicines

Ep192: Kate Haviland on Following the Science to Precision Immunology

Ep191: Emily Conley on Small Molecules to Correct a Rare Kidney Disease

Ep190: Neil Kumar on Building a Rare Disease Drug Company